Vectors Research Management’s AstraZeneca AZN Stock Holding History

Vectors Research Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	-$20K	–	165
2022 Q2	$20K	Hold	150	–	–	0.01%	283
2022 Q1	$20K	Hold	150	–	–	﹤0.01%	289
2021 Q4	$17K	Hold	150	–	–	﹤0.01%	352
2021 Q3	$18K	Hold	150	–	–	﹤0.01%	314
2021 Q2	$18K	Hold	150	–	–	﹤0.01%	320
2021 Q1	$15K	Sell	150 -100	-40%	-$10.1K	﹤0.01%	303
2020 Q4	$25K	Sell	250 -25	-9%	-$2.65K	0.01%	250
2020 Q3	$30K	Buy	275 +250	+1,000%	+$27.8K	0.01%	210
2020 Q2	$3K	Buy	+25	New	+$2.58K	﹤0.01%	370

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Vectors Research Management's AZN Position: Q3 2022 in Review

Vectors Research Management sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 150 shares — an estimated $20K sold.

Vectors Research Management first reported a position in AZN in Q2 2020 and held it in 9 quarters. The position peaked at $30K in Q3 2020. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

Vectors Research Management reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 150 AstraZeneca shares in Q3 2022, an estimated $20K.
Vectors Research Management first reported a position in AstraZeneca in Q2 2020 and held it in 9 quarters.
Vectors Research Management's AstraZeneca position peaked at $30K in Q3 2020.
965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.